Deschamps A, Marin C, Gerbault Q, Toullec C, Clatot F, Bernadach M, Fayette J, Daste A, Ceruse P, Burgy M, Champetier C, Abdeddaim C, Saada-Bouzid E, Tchiknavorian X, Zanetta S, Auquier P, Ciccolini J, Salas S

Cancer Chemother Pharmacol. 2026 04 29;96(1):

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

Fayette J, Cropet C, Toullec C, Burgy M, Bruyas A, Sire C, Lagrange A, Clatot F, Vinches M, Iacob M, Martin L, Kaminsky MC, Vansteene D, Salas S, Champagnac A, Saintigny P, Gautier J, Pérol D, Bourhis J

ESMO Open. 2026 04 9;11(4):106946

Inverse Correlation between Endoplasmic Reticulum Stress Intensity and Antitumor Immune Response with Ruthenium(II)-Based Photosensitizers for the Photodynamic Therapy of Head and Neck Squamous Cell Carcinoma.

Thibaudeau C, Bour C, Scarpi-Luttenauer M, Mesdom P, Karges J, Gandioso A, Zhou L, Harlepp S, Detappe A, Burgy M, Martin S, Mellitzer G, Gaiddon C, Gasser G, Jung AC

J Med Chem. 2025 11 19;:

Nuclear factor E2 p45-related factor (NRF2) and peroxiredoxin 6 tissular expression as prognostic biomarkers for advanced HPV-negative squamous cell carcinoma of the oropharynx.

Philouze P, Benzerdjeb N, Malésys C, Wozny AS, Soumboundou M, Kobler A, Jung AC, Burgy M, Céruse P, Alphonse G, Rodriguez-Lafrasse C

Transl Oncol. 2025 11 3;63:102595

Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate of Patients With Metastatic Renal Cell Carcinomas.

Moinard-Butot F, Oriel M, Tricard T, Cazzato RL, Pierard L, Gaillard V, Werle P, Lindner V, Martin S, Schuster C, Roy C, Burgy M, Anthony A, Bigot C, Boudier P, Fritsch A, Olland A, Malouf G, Lang H, Barthélémy P

Clin Genitourin Cancer. 2024 06 5;22(5):102134

Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.

Borel C, Sun XS, Coutte A, Bera G, Sire C, Zanetta S, Alfonsi M, Janoray G, Chatellier T, Garcia-Ramirez M, Gherga E, Hammoud Y, Burgy M, Etienne-Selloum N, Pechery A, Girard-Calais MH, Velten M, Pignon JP, Wanneveich M, Bourhis J

Radiother Oncol. 2024 05 18;:110329

Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.

Hélène C, Conrad O, Pflumio C, Borel C, Voegelin M, Bernard A, Schultz P, Onea MA, Jung A, Martin S, Burgy M

BMC Cancer. 2023 12 8;23(1):1209

A novel ΔNp63-dependent immune mechanism improves prognosis of HPV-related head and neck cancer.

Mourtada J, Lony C, Nicol A, De Azevedo J, Bour C, Macabre C, Roncarati P, Ledrappier S, Schultz P, Borel C, Burgy M, Wasylyk B, Mellitzer G, Herfs M, Gaiddon C, Jung AC

Front Immunol. 2023 10 25;14:1264093

Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities.

Imperiale A, Berti V, Burgy M, Cazzato RL, Piccardo A, Treglia G

Rev Endocr Metab Disord. 2023 09 16;:

Tumor-Suppressive and Immunomodulating Activity of miR-30a-3p and miR-30e-3p in HNSCC Cells and Tumoroids.

Conrad O, Burgy M, Foppolo S, Jehl A, Thiéry A, Guihard S, Vauchelles R, Jung AC, Mourtada J, Macabre C, Ledrappier S, Chenard MP, Onea MA, Danic A, Dourlhes T, Thibault C, Schultz P, Dontenwill M, Martin S

Int J Mol Sci. 2023 07 6;24(13):

Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction.

Jehl A, Conrad O, Burgy M, Foppolo S, Vauchelles R, Ronzani C, Etienne-Selloum N, Chenard MP, Danic A, Dourlhes T, Thibault C, Schultz P, Dontenwill M, Martin S

Cells. 2023 02 24;12(5):

Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.

Gaillard V, Lhuillier A, Bigot C, Pierard L, Trensz P, Burgy M, Schuster C, Malouf G, Fritsch A, Lang H, Tricard T, Borchiellini D, Geoffrois L, Barthelemy P

Support Care Cancer. 2022 Apr 29;:

Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma.

Burgy M, Jehl A, Conrad O, Foppolo S, Bruban V, Etienne-Selloum N, Jung AC, Masson M, Macabre C, Ledrappier S, Burckel H, Mura C, Noël G, Borel C, Fasquelle F, Onea MA, Chenard MP, Thiéry A, Dontenwill M, Martin S

Cancers (Basel). 2021 Jun 18;13(12):

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.

Carinato H, Burgy M, Ferry R, Fischbach C, Kalish M, Guihard S, Brahimi Y, Flesch H, Bronner G, Schultz P, Frasie V, Thiéry A, Demarchi M, Petit T, Jung AC, Wagner P, Coliat P, Borel C

Front Oncol. 2021 ;11:714551

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Borel C, Jung AC, Burgy M

Cancers (Basel). 2020 Sep 21;12(9):

Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report.

Burgy M, Chenard MP, Noël G, Bourahla K, Schott R

J Med Case Rep. 2019 Jun 28;13(1):202

Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer.

Borel C, Regnier-Gavier O, Carinato H, Guihard S, Antoni D, Demarchi M, Sirlin F, Exinger D, Petit-Jean E, Thiery A, Bronner G, Schultz P, Flesch H, Frasie V, Prébay D, Petit T, Jung AC, Burgy M, Coliat P

Oncotarget. 2018 Dec 25;9(101):37581-37588